Online citations, reference lists, and bibliographies.
← Back to Search

Polyelectrolyte Stabilized Multilayered Liposomes For Oral Delivery Of Paclitaxel.

S. Jain, D. Kumar, N. K. Swarnakar, K. Thanki
Published 2012 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Paclitaxel (PTX) loaded layersome formulations were prepared using layer-by-layer assembly of the polyelectrolytes over liposomes. Stearyl amine was utilized to provide positive charge to the liposomes, which were subsequently coated with anionic polymer polyacrylic acid (PAA) followed by coating of cationic polymer polyallylamine hydrochloride (PAH). Optimization of various process variables were carried out and optimized formulation was found to have particle size of 226 ± 17.61 nm, PDI of 0.343 ± 0.070, zeta potential of +39.9 ± 3.79 mV and encapsulation efficiency of 71.91 ± 3.16%. The developed formulation was further subjected to lyophilization using a universal stepwise freeze drying cycle. The lyophilized formulation was found to be stable in simulated gastrointestinal fluids and at accelerated stability conditions. In vitro drug release studies revealed that layersome formulation was able to sustain the drug release for 24 h; release pattern being Higuchi kinetics. Furthermore, cell culture experiments showed higher uptake of layersomes from lung adenocarcinoma (A549) cell lines as compared to free drug. This was subsequently corroborated by MTT assay, which revealed IC50 value of 29.37 μg/ml for developed layersome formulation in contrast to 35.42 μg/ml for free drug. The in vivo pharmacokinetics studies revealed about 4.07 fold increase in the overall oral bioavailability of PTX as compared to that of free drug. In vivo antitumor efficacy in DMBA induced breast tumor model showed significant reduction in the tumor growth as compared to the control and comparable to that of i.v. Taxol(®). In addition, the toxicity studies were carried out to confirm the safety profile of the developed formulation and it was found to be significantly higher as compared to Taxol(®). Therefore, the developed formulation strategy can be fruitfully exploited to improve the oral deliverability of difficult-to deliver drugs.
This paper references
10.1016/j.ijpharm.2011.05.066
Oral peptide delivery by tetraether lipid liposomes.
J. Parmentier (2011)
10.1211/0022357022935
Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects
M. Vertzoni (2004)
10.1046/J.1523-1747.2003.12057.X
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
R. Kunstfeld (2003)
10.3109/10717544.2011.596585
N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin
Aiwen Huang (2011)
10.1016/S0378-4347(98)00566-0
Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography.
S. Lee (1999)
10.1016/J.ADDR.2006.09.017
Freeze-drying of nanoparticles: formulation, process and storage considerations.
W. Abdelwahed (2006)
Stabilization of the nanodrug delivery systems by lyophilization using universal step-wise freeze drying cycle
S Jain (2011)
10.1146/ANNUREV.BB.09.060180.002343
Comparative properties and methods of preparation of lipid vesicles (liposomes).
F. Szoka (1980)
10.1016/j.biomaterials.2009.12.043
The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(gamma-benzyl L-glutamate)-b-hyaluronan polymersomes.
K. K. Upadhyay (2010)
A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors.
J. Cassidy (1998)
10.2147/IJN.S19917
Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation
M. Niu (2011)
Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat.
Q. V. van Hoesel (1984)
10.2147/IJN.S13031
Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats
A. Rudra (2010)
10.1016/S0927-7765(01)00303-4
Interaction of paclitaxel with DSPC in monolayers at the air/water interface at different temperatures
Tzung-Han Chou (2002)
Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.
A. Gabizon (1982)
10.1073/PNAS.94.5.2031
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
10.1016/J.IJPHARM.2006.02.027
A folate receptor-targeted liposomal formulation for paclitaxel.
J. Wu (2006)
Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma
سمر عمر رباح (2010)
10.1159/000169072
Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
A. Mérouani (1997)
10.1080/03639040802244326
Development and in vitro characterization of liposomes coated with thiolated poly(acrylic acid) for oral drug delivery.
M. Werle (2009)
10.1016/J.MOLSTRUC.2004.11.075
The influence of temperature, cholesterol content and pH on liposome stability
W. Sułkowski (2005)
10.1166/JNN.2006.440
Improved oral delivery of paclitaxel following administration in nanoemulsion formulations.
S. Tiwari (2006)
10.1007/s11095-008-9763-4
Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats
D. R. Kalaria (2008)
10.1016/J.JCONREL.2004.03.013
Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles.
Yong Woo Cho (2004)
10.1016/b978-0-444-82917-7.x5000-5
Medical applications of liposomes
D. Lasič (1998)
10.1007/s11095-005-4581-4
Formulating Paclitaxel in Nanoparticles Alters Its Disposition
Teng Kuang Yeh (2005)
10.1016/0024-3205(93)90573-L
Study of in vitro and in vivo stability of liposomes loaded with calcitonin or indium in the gastrointestinal tract.
A. Ariën (1993)
Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique.
D. Pandita (2009)
10.1016/j.biomaterials.2010.09.037
The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen.
A. Jain (2011)
10.1109/TNB.2004.824273
Liposome-based nanocapsules
T. Ruysschaert (2004)
10.1016/J.EJPB.2003.11.002
Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin.
J. Choi (2004)
10.1007/s10517-008-0066-x
Toxic effect of an antitumor drug paclitaxel on morphofunctional characteristics of the liver in rats
L. A. Ermolaeva (2008)
10.1016/j.colsurfb.2008.09.023
Efficient formation of giant liposomes through the gentle hydration of phosphatidylcholine films doped with sugar.
K. Tsumoto (2009)
10.1016/S0168-3659(01)00440-0
Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers.
L. Mu (2001)
10.1039/B700410A
Layer-by-layer assembly as a versatile bottom-up nanofabrication technique for exploratory research and realistic application.
K. Ariga (2007)
10.1016/J.IJPHARM.2007.05.037
Layersome: development and optimization of stable liposomes as drug delivery system.
M. Ciobanu (2007)
10.1016/J.IJPHARM.2006.05.046
Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Byung-Chul Choi (2006)
10.1002/jps.21581
Local delivery of modified paclitaxel-loaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia.
L. Mei (2009)
10.1007/s11095-007-9409-y
Enhanced Oromucosal Delivery of Progesterone Via Hexosomes
N. K. Swarnakar (2007)
10.1016/S0009-3084(00)00135-3
Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy.
C. Socaciu (2000)
10.1093/ANNONC/MDL104
Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
M. Green (2006)
Clinical toxicities encountered with paclitaxel (Taxol).
E. Rowinsky (1993)
10.1016/j.jconrel.2009.08.010
Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis.
E. Roger (2009)
10.1016/J.IJPHARM.2005.02.021
Effect of cholesterol and ethanol on dermal delivery from DPPC liposomes.
J. López-Pinto (2005)
10.1021/mp8002539
Polyelectrolyte coated multilayered liposomes (nanocapsules) for the treatment of Helicobacter pylori infection.
P. Jain (2009)



This paper is referenced by
10.1021/bm401580k
Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration.
A. Agrawal (2014)
10.1201/9781315371276-8
Multilayer nanocapsules as a vehicle for release of bioactive compounds
Ana Cristina Pinheiro (2016)
10.1007/978-3-030-01775-0_9
Oral Nanotherapeutics for Cancer with Innovations in Lipid and Polymeric Nanoformulations
Alexander J. Donovan (2019)
10.1016/j.jconrel.2013.12.030
Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy.
C. Luo (2014)
10.1039/C5RA14588K
Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies
Guihua Fang (2015)
10.7324/JAPS.2015.50704
Formulation and in vitro evaluation of berberine containing liposome optimized by 32 full factorial designs
G. Sailor (2015)
10.23937/2572-3278.1510039
Potential Therapeutic Effects and Bioavailability of Wogonin, the Flavone of Baikal Skullcap
Gharari Zahra (2019)
10.7150/thno.34953
Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer
Chao Hong (2019)
10.2217/nnm.13.225
Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery.
H. Harde (2014)
10.1016/j.carbpol.2017.11.098
Surfactant-stable and pH-sensitive liposomes coated with N-succinyl-chitosan and chitooligosaccharide for delivery of quercetin.
J. Seong (2018)
10.5897/AJPP2013.3951
Influence of polyethylene glycol-8-lauryl ester in the structural lipid of the elastic liposomes
R. M. Barbosa (2014)
10.1016/j.jmst.2020.05.062
Reversible grafting of antibiotics onto contact lens mediated by labile chemical bonds for smart prevention and treatment of corneal bacterial infections
Bailiang Wang (2021)
10.1016/B978-0-323-47720-8.00017-1
Nanotechnology for oral delivery of anticancer drugs: an insight potential
M. Gupta (2017)
10.1007/s11095-013-1280-4
Development of 2D and 3D Mucus Models and Their Interactions with Mucus-Penetrating Paclitaxel-Loaded Lipid Nanocapsules
Anne-Claire Groo (2013)
10.1517/17425247.2013.752354
Paclitaxel drug delivery systems
Zhiping Zhang (2013)
10.1186/2228-5326-3-45
Emerging applications of nanoparticles for lung cancer diagnosis and therapy
U. K. Sukumar (2013)
Chapter 2 Recent Advances in Tumor Targeting Approaches
K. Thanki (2018)
10.7324/japs.2020.10617
Solid lipid nanoparticles: Preparation techniques, their characterization, and an update on recent studies
Koduru Trideva Sastri (2020)
10.1016/j.nano.2017.03.001
Milk-derived exosomes for oral delivery of paclitaxel.
A. Agrawal (2017)
10.1080/09205063.2018.1475941
PTX-loaded three-layer PLGA/CS/ALG nanoparticle based on layer-by-layer method for cancer therapy
F. Wang (2018)
10.1016/J.JDDST.2018.09.019
Preparation and characterization of novel pseudo ceramide-based nanostructured lipid carriers for transdermal delivery of apigenin
N. Lee (2018)
10.1002/AIC.14770
Layer‐by‐layer approaches to staging medicine from surfaces
P. Hammond (2015)
10.1208/s12249-020-01671-7
EGFR Targeted Paclitaxel and Piperine Co-loaded Liposomes for the Treatment of Triple Negative Breast Cancer
Ankita Sanjay Burande (2020)
10.1039/C5RA04762E
Cyclosporine A loaded self-nanoemulsifying drug delivery system (SNEDDS): implication of a functional excipient based co-encapsulation strategy on oral bioavailability and nephrotoxicity
S. Jain (2015)
10.2147/DDDT.S201453
Solutol®HS15+pluronicF127 and Solutol®HS15+pluronicL61 mixed micelle systems for oral delivery of genistein
Pinggang Ding (2019)
10.1007/978-3-319-11355-5_2
Recent Advances in Tumor Targeting Approaches
K. Thanki (2015)
10.1208/s12249-016-0522-2
In Vitro and Ex Vivo Evaluations of Lipid Anti-Cancer Nanoformulations: Insights and Assessment of Bioavailability Enhancement
A. Jain (2016)
10.1016/B978-0-12-820658-4.00013-3
Inhalable hybrid nanocarriers for respiratory disorders
P. Maurya (2020)
10.1039/C5RA28018D
Enhanced hepatic-targeted delivery via oral administration using nanoliposomes functionalized with a novel DSPE–PEG–cholic acid conjugate
Y. Li (2016)
10.1039/C4RA04237A
Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity
S. Jain (2014)
10.1016/j.carbpol.2015.10.080
Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
Chander Parkash Dora (2016)
10.2217/nnm.14.177
Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration.
H. Harde (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar